Carcinoid tumor of lung and BRCA mutation: a case report

Mohammed Z. Shariff, Diana Curras-Martin, Natasha Campbell, Varsha Gupta, John D. Mikhail, Michael J. Levitt and Mohammad A. Hossain

Abstract

Background: A BRCA mutation is a mutation in either of the BRCA1 or BRCA2 genes, which are tumor suppressor genes. Hundreds of different types of mutations in these genes have been identified, some of which have been determined to be harmful, whereas others have no proven impact. BRCA mutations are well known to be associated with breast, uterine, and ovarian cancers along with some nongynecological malignancies involving the peritoneum, prostate, pancreas, skin, stomach, and rectum. However, there are no reported cases to date of an association between carcinoid tumors and a BRCA mutation.

Case presentation: Our patient was a 33-year-old White woman with BRCA2 mutation who presented to her primary care physician for evaluation of abdominal pain. She underwent computed tomography of her abdomen and pelvis, which showed an incidental finding of infrahilar mass along with renal stones. Further workup with bronchoscopy and biopsy of the mass confirmed it to be a carcinoid tumor of the lung.

Conclusions: No literature thus far exists describing a connection between BRCA mutations and carcinoid tumors. Early diagnosis and prompt treatment of carcinoid tumors are proven to have impact on survival and prognosis of these patients.

Keywords: Carcinoid tumor, BRCA mutation, Infrahilar mass

Background

Carcinoid tumors, also known as neuroendocrine tumors (NETs), are an uncommon group of pulmonary neoplasms accounting for 1–2% of all lung cancers in adults and around 20–30% of all NETs [1–4]. These tumor cells are most probably derived from peptide- and amine-producing neuroendocrine cells. NETs can be seen throughout the body, but the most common site is the gastrointestinal tract, and the second most common site is the lung. Multiple previous studies showed association of carcinoid tumor with family history of cancer, body mass index, diabetes mellitus, cigarette smoking, and alcohol consumption [5–8]. However, to the best of our knowledge, there has been no study or case reported yet implicating possible association of carcinoid tumors with BRCA gene mutation. With this case report, our objective is to create awareness among primary care physicians that carcinoid tumors can occur in patients with BRCA gene mutations, because early diagnosis and prompt treatment of these tumors can have high impact on prognosis.

Case presentation

Our patient was a 33-year-old White woman with BRCA2 gene mutation status. She presented to her primary care doctor for abdominal and back pain after bilateral prophylactic mastectomy. She had a strong family history of BRCA2-positive breast cancer in two of her aunts and one cousin. Her physical examination revealed that her vital signs were normal, and her abdominal examination was unremarkable except for mild nonspecific lower abdominal tenderness. For evaluation of lower abdominal pain and back pain, she underwent computed tomography (CT) of the abdomen and pelvis, which showed nonobstructing bilateral renal calculi and incidentally showed right infrahilar adenopathy. She underwent further CT of the chest with contrast enhancement, which revealed a right hilar mass measuring 3 × 2.2 cm and suspicious for...
malignancy (Fig. 1). Routine laboratory blood work was within normal limits and unremarkable, and possible infectious etiology was also ruled out (Table 1).

Clinical findings
A pulmonologist was consulted for further evaluation of the infrapulmonary mass. On further inquiry, the patient reported occasional nonproductive cough with expiratory wheezing. She underwent electromagnetic navigational bronchoscopy for biopsy of her 2-cm mass in the right hilum. Biopsy confirmed a carcinoid tumor of the right lung. Atypical cells were positive for Cam5.2, thyroid transcription factor 1, synaptophysin, chromogranin, and CD56. The patient was then evaluated by a thoracic surgeon for possible surgical excision of the mass. She underwent right video-assisted thoracic surgery (VATS) with right thoracotomy, right middle and lower lobectomy, and lymph node resection.

Diagnostic assessment
The pathology report of the lung nodule confirmed it to be a typical carcinoid tumor with metastasis to one subcarinal lymph node (Fig. 2). A histopathological section of the lung nodule showed a neoplastic proliferation arranged in a nested and organoid pattern. The cells had monomorphic nuclei with “salt-and-pepper” chromatin and scant eosinophilic cytoplasm. Mitotic activity was low, and there was no necrosis. The patient’s tumor, node, metastasis staging is T2aN2M0.

Therapeutic intervention
As per discussion with the patient and according to National Comprehensive Cancer Network (NCCN) guidelines, the patient would not receive any chemotherapy currently and would be closely followed by an oncologist.

Table 1 Summary of laboratory results

| Test                          | Result     | Reference range          |
|-------------------------------|------------|--------------------------|
| White blood cell count        | 9100/μl    | 4500–11,000/μl           |
| Neutrophils                   | 54.5%      | 50–70%                   |
| Lymphocytes                   | 34.2%      | 25–43%                   |
| Monocytes                     | 8%         | 0–9%                     |
| Eosinophils                   | 2.3%       | 0–9%                     |
| Basophils                     | 0.7%       | 0–2%                     |
| Hemoglobin                    | 13.6 g/dl  | 12–16 g/dl               |
| Hematocrit                    | 41.3%      | 35–48%                   |
| Platelet count                | 374,000/μl | 140,000–440,000/μl       |
| Blood urea nitrogen           | 6 mg/dl    | 5–25 mg/dl               |
| Serum creatinine              | 0.66 mg/dl | 0.44–1.00 mg/dl          |
| Serum sodium                  | 136 mmol/L | 136–145 mmol/L           |
| Serum potassium               | 3.8 mmol/L | 3.5–5.2 mmol/L           |

Follow-up and outcomes
The patient has had two follow-up appointments with her oncologist since the VATS procedure. After discussion with the patient and according to NCCN guidelines, the patient did not receive any adjuvant chemotherapy. The plan moving forward would be close surveillance with serial CT scans (3–6-month intervals) and chromogranin A measurements.

Discussion
Carcinoid syndrome represents a constellation of symptoms that are seen in patients with NETs. The symptoms are exhibited because of release of chemical mediators, and as many as 40 such mediators have been identified in the pathophysiology of carcinoid syndrome [9]. The most prominent of these are serotonin, histamine, tachykinins, kallikrein, and prostaglandins. The
Carcinoid tumors have been well studied from the early 18th century. There have been multiple case reports and studies about carcinoid tumors of the lung; however, to the best of our knowledge, there is no literature thus far describing a connection between BRCA mutations and carcinoid tumors. A BRCA mutation is a mutation in either of the BRCA1 or BRCA2 genes, which are tumor suppressor genes [12]. Hundreds of different types of mutations in these genes have been identified, some of which have been determined to be harmful, whereas others have no proven impact. BRCA mutations are well known to be associated with breast, uterine, and ovarian cancers along with some nongynecological malignancies involving the peritoneum, prostate, pancreas, skin, stomach, and rectum. The present case report highlights a possible association between carcinoid tumors and BRCA2 gene mutation. Our patient had heterozygous germline BRCA2 mutation c.4884_4885del. This observation can be incidental and unrelated; however, further studies and vigilant case reporting can solidify this association.

Carcinoid tumors are commonly seen in the gastrointestinal tract with frequent metastasis to liver. The first description of carcinoid tumors was in the late 18th century by Lubarsch, followed by Oberndorfer in 1907 [13]. In the early 1950s, there were six reported cases of bronchial carcinoid. In 1960, Maurice Joseph and R. R. Taylor reported a case of a 62-year-old woman who initially presented in 1952 with a 3-month history of cough and a 19-kg weight loss. A chest x-ray was suggestive of a tumor involving the upper lobe of the lung in that patient. Bronchoscopy was performed, which did not show any definitive disease. She was advised to undergo thoracotomy, which she refused, and she sought discharge against medical advice. She was followed as an outpatient, and her clinical state did not alter until November 1958, when she complained of pain in the left chest and worsening dyspnea. She refused admission at that time. However, she was hospitalized 2 months later with complaints of severe dyspnea, intermittent diarrhea, intermittent flushing of the upper face and hemithorax, and episodes of wheezing. At this stage, diagnosis of functioning carcinoid was suggested, which was confirmed by elevated levels of 5-hydroxyindoleacetic acid in the urine. She was treated symptomatically with diuretics, nicotinic acid, digoxin, chlorpromazine, and mersaryl. The patient did not want to undergo any invasive procedures, so she was discharged to a nursing home at the request of her family, where she died a few months later. The postmortem report confirmed the tumor to be a carcinoid tumor of the left lung involving the entire lung with metastasis to regional lymph nodes. That was the first reported case of lung carcinoid, to the best of our knowledge. Compared with our patient, who received prompt VATS with excision of the tumor, the definitive treatment was not provided, because the patient refused invasive procedures, leading to death with distant metastasis.

The definitive treatment for lung carcinoid depends on the extent of disease, pulmonary reserve, and distant metastasis [14]. For patients with localized lung NETs, surgical resection is the preferred treatment modality, provided there is adequate pulmonary reserve. For patients whose condition does not allow complete surgical resection, options for control of tumor growth include radiotherapy, with or without concurrent chemotherapy, and palliative endobronchial resection of the tumor [15, 16]. Our patient had a small carcinoid tumor localized to the lung with a good pulmonary reserve; hence, she was promptly treated with complete resection of the tumor.

The role of adjuvant chemotherapy after complete resection of the lung NET is not recommended, owing to total lack of prospective randomized controlled trials. However, there are a number of retrospective studies to study the role of adjuvant chemotherapy, but most of those studies have not found a benefit from adjuvant chemotherapy [14–18]. Most of the patients included in the retrospective studies had a large NET of the lung that might have been responsible for the lack of benefit from the adjuvant chemotherapy. However, our patient has a small carcinoid tumor of the right lung with metastasis to only one subcarinal lymph node, so she might benefit from the adjuvant chemotherapy. However, as per the discussion with the patient, she did not receive any chemotherapy and would be closely monitored by her oncologist.

Conclusions
No literature exists showing a connection between BRCA mutations and carcinoid tumors; thus, further studies and vigilant case reports are needed to solidify the association between them. Patients with BRCA mutation should be examined with a careful workup for carcinoid tumor in appropriate clinical scenarios. Delay
in diagnosis may possibly result in unfavorable prognosis, which may ultimately lead to death. Early diagnosis and prompt treatment with complete surgical resection have been proven to prolong survival.

Abbreviations
CT: Computed tomography; NCCN: National Comprehensive Cancer Network; NET: Neuroendocrine tumor; VATS: Video-assisted thoracic surgery

Funding
This project was not supported by any grants or funding agencies.

Authors’ contributions
Each author was individually involved and participated in drafting the manuscript and revising it critically for important intellectual content and gave final approval of the version to be published. Each author has agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. All authors are aware of and approve the manuscript being submitted for publication. JDM and MAH encouraged MZS, DCM, NC, and VG to learn about carcinoid tumors of the lung and BRCA gene mutations. All authors discussed the medical literature. MZS presented the idea. MZS, DCM, NC, and VG wrote the manuscript with input from all authors.

Ethics approval and consent to participate
Not applicable.

Consent for publication
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 8 December 2018 Accepted: 14 March 2019
Published online: 01 May 2019

References
1. Quaedvlieg PF, Visser O, Lamers CB, et al. Epidemiology and survival in patients with carcinoid disease in The Netherlands: An epidemiological study with 2391 patients. Ann Oncol. 2001;12:1212-25.
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer. 2003;97:934.
3. Hemminki K, Li X. Incidence trends and risk factors of carcinoid tumors: a nationwide epidemiologic study from Sweden. Cancer. 2001;92:2204.
4. Hauso O, Gustafsson BI, Kidd M, et al. Neuroendocrine tumor epidemiology: contrasting Norway and North America. Cancer. 2006;113:2655.
5. Beasley MB, Thunnissen FB, Brambilla E, et al. Pulmonary atypical carcinoid: predictors of survival in 106 cases. Hum Pathol. 2000;31:1255.
6. Froudarakis M, Fournel P, Burgard G, et al. Bronchial carcinoids: a review of 22 cases. Oncology. 1996;53:153.
7. Hassan MM, Phan A, Li D, et al. Risk factors associated with neuroendocrine tumors: a U.S.-based case-control study. Int J Cancer. 2008;123:867.
8. Leoncini E, Carillo G, La Vecchia C, et al. Risk factors for neuroendocrine neoplasms: a systematic review and meta-analysis. Ann Oncol. 2016;27:68.
9. Modlin IM, Kidd M, Latich I, et al. Current status of gastrointestinal carcinoids. Gastroenterology. 2005;128:1717.
10. von der Ohe MR, Camilleri M, Kvols LK, Thomforde GM. Motor dysfunction of the small bowel and colon in patients with the carcinoid syndrome and diarrhea. N Engl J Med. 1993;329:1073.
11. Warner RRP. Carcinoid tumors. In: Berk JE, editor. Bockus gastroenterology, vol. 3. 4th ed. Philadelphia: Saunders; 1985. p. 1874–86.
12. Borg Å, Halle RW, Malone KE, Caparu M, Diep A, Tömören T, Teraoka S, Begg CB, Thomas DC, Concannon P, Møllempjærer L, Bernstein L, Tellhed L, Xue S, Olson ER, Liang X, Dølø J, Barresen-Dale AL, Bernstein JL. Characterization of BRCA1 and BRCA2 deleterious mutations and variants of unknown clinical significance in unilateral and bilateral breast cancer: the WECARE Study. Hum Mutat. 2010;31(3):E1200–40.
13. Joseph M, Taylor RR. Argentaffinoma of the lung with carcinoid syndrome. Br Med J. 1962;2(198):568–71.
14. Divisi D, Crisci R. Carcinoid tumors of the lung and multimodal therapy. Thorac Cardiovasc Surg. 2005;53:168.
15. Filoso PL, Oliaro A, Ruffini E, et al. Outcome and prognostic factors in bronchial carcinoids: a single-center experience. J Thorac Oncol. 2013;8:1282.
16. Mackley HB, Videtic GM. Primary carcinoid tumors of the lung: a role for radiotherapy. Oncology (Williston Park). 2006;20:1537.
17. Carretta A, Ceresoli GL, Arrigoni G, et al. Diagnostic and therapeutic management of neuroendocrine lung tumors: a clinical study of 44 cases. Lung Cancer. 2002;29:217.
18. Perkins P, Kemp BL, Putnam JB Jr, Cox JD. Pretreatment characteristics of carcinoid tumors of the lung which predict aggressive behavior. Am J Clin Oncol. 1997;20:285.